Paul G. Richardson
Harvard University
Internal medicineSurgeryOncologyAdverse effectImmunologyLenalidomideMultiple myelomaBortezomibProteasome inhibitorPomalidomideThalidomideBone marrowDexamethasonePopulationTransplantationCancer researchMedicineBiologyGastroenterologyPharmacology
1,743Publications
207H-index
136kCitations
Publications 1707
Newest
#1Jesus G. Berdeja (Sarah Cannon Research Institute)H-Index: 33
#2Jacob P. Laubach (Harvard University)H-Index: 50
Last. Ajai Chari (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 26
view all 0 authors...
Summary null Relapsed and refractory multiple myeloma (RRMM) presents a therapeutic challenge due to the development of drug resistance. Panobinostat is an oral histone deacetylase inhibitor (HDACi) that affects multiple cellular pathways and has demonstrated the ability to resensitise refractory-multiple myeloma cells in preclinical studies, as well as in patients with RRMM in clinical trials. Synergy of panobinostat with a number of different classes of anti-myeloma drugs (proteasome inhibitor...
Source
#1Edward Richardson (Quinnipiac University)H-Index: 1
#2David García-Bernal (University of Murcia)H-Index: 21
Last. Massimo IacobelliH-Index: 18
view all 0 authors...
Introduction null Defibrotide (DF) is a polyribonucleotide with antithrombotic, pro-fibrinolytic, and anti-inflammatory effects on endothelium. These effects and the established safety of DF present DF as a strong candidate to treat viral and post-infectious syndromes involving endothelial dysfunction. null Areas covered null We discuss DF and other therapeutic agents that have the potential to target endothelial components of pathogenesis in viral and post-infectious syndromes. We introduce def...
Source
#1Sara FernándezH-Index: 8
Last. Enric CarrerasH-Index: 62
view all 0 authors...
BACKGROUND: Endotheliopathy is a key element in COVID-19 pathophysiology, contributing to both morbidity and mortality. Biomarkers distinguishing different COVID-19 phenotypes from sepsis syndrome remain poorly understood. OBJECTIVE: To characterize circulating biomarkers of endothelial damage in different COVID-19 clinical disease stages compared with sepsis syndrome and normal volunteers. METHODS: Patients with COVID-19 pneumonia (n = 49) were classified into moderate, severe, or critical ...
Source
#1Larysa Sanchez (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 2
#2Xavier LeleuH-Index: 72
Last. Ivan SpickaH-Index: 31
view all 0 authors...
Source
#1David García-Bernal (University of Murcia)H-Index: 21
#2Edward Richardson (Quinnipiac University)H-Index: 1
Last. José M. Moraleda (University of Murcia)H-Index: 34
view all 0 authors...
Source
#1Paul G. Richardson (Harvard University)H-Index: 207
#2Shaji Kumar (Mayo Clinic)H-Index: 123
Last. Bartrum W BakerH-Index: 4
view all 0 authors...
PURPOSEThe double-blind, placebo-controlled, phase III TOURMALINE-MM1 study demonstrated a statistically significant improvement in progression-free survival with ixazomib-lenalidomide-dexamethason...
Source
Introduction There continues to be an exponential rise in the number of small molecule drugs that contain either a fluorine atom or a fluorinated fragment. While the unique properties of fluorine enable the precise modulation of a molecule's physicochemical properties, strategic bioisosteric replacement of fragments with fluorinated moieties represents an area of significant growth.Areas Covered This review discusses the strategic employment of fluorine-substitution in the design and development...
Source
#1Pedro Castro (University of Barcelona)H-Index: 19
#2Marta Palomo (University of Barcelona)H-Index: 13
Last. Josep M. Nicolás (University of Barcelona)H-Index: 25
view all 0 authors...
Patients with COVID-19 present a wide spectrum of disease severity, from asymptomatic cases in the majority to serious disease leading to critical care and even death. Clinically, four different scenarios occur within the typical disease timeline: first, an incubation and asymptomatic period; second, a stage with mild symptoms due mainly to the virus itself; third, in up to 20% of the patients, a stage with severe symptoms where a hyperinflammatory response with a cytokine storm driven by host i...
Source
#1Jiye Liu (Harvard University)H-Index: 8
#2Teru Hideshima (Harvard University)H-Index: 133
Last. Kenneth C. Anderson (Harvard University)H-Index: 64
view all 20 authors...
Immunomodulatory drugs (IMiDs) have markedly improved patient outcome in multiple myeloma (MM); however, resistance to IMiDs commonly underlies relapse of disease. Here, we identify that tumor necrosis factor (TNF) receptor-associated factor 2 (TRAF2) knockdown (KD)/knockout (KO) in MM cells mediates IMiD resistance via activation of noncanonical nuclear factor κB (NF-κB) and extracellular signal-regulated kinase (ERK) signaling. Within MM bone marrow (BM) stromal cell supernatants, TNF-α induce...
Source
Source